A quotation for “doxycycline 100 mg with lactic acid bacillus” leaves critical questions unanswered: which doxycycline salt, which bacterial strain, what viable count reaches expiry, and whether the fixed-dose product is authorised for sale. By checking the product identity, compatibility evidence, quality records, and supply controls in sequence, you can separate a qualified manufacturer from a supplier offering only a catalogue and sample.
Key takeaways
- Confirm authorization for the exact fixed-dose combination in your target market.
- Compare formulation compatibility and interaction controls before comparing prices.
- Request evidence that probiotic potency survives manufacture and storage.
- Review batch-release documents, licences, testing records, and supply terms.
Verify the exact combination, strength, and market authorization
A license to manufacture doxycycline and a separate license for a probiotic do not prove approval for a doxycycline and lactic acid bacillus capsule. Confirm that the exact fixed-dose combination is authorized in your target market, not merely that both ingredients appear in the manufacturer’s portfolio.
Ask for the product-specific license or marketing authorization and compare its approved details with the proposed offer:
- Doxycycline salt and strength in milligrams per capsule
- Named lactic acid bacillus species and strain, with the declared viable count in CFU per dose
- Approved dosage form, such as immediate-release hard gelatin capsule
- Approved indication, route, age restrictions, and dosing instructions
- Excipients, capsule shell, pack size, storage conditions, and shelf life
Check the authorization number in the issuing regulator’s public database or confirm it directly with the regulator. The approved composition must match the manufacturer’s master formula, label, carton, and export artwork; a changed strength, strain, indication, or dosage form can make the offer a different product.
Treat claims such as “prevents antibiotic-associated diarrhoea,” “restores gut flora,” or “protects the stomach” as claims requiring product- and strain-specific authorization and evidence. Evidence for another probiotic strain cannot validate this combination.
If the manufacturer supplies only a generic GMP certificate, sample, or catalogue entry, it has not established approval for the product you intend to buy.
Check the formulation and interaction details before comparing prices
A quotation that says “doxycycline 100 mg” is incomplete. It must identify the salt, assay basis, probiotic strain, viable count, excipients, capsule type, and instructions that govern use.
1. Confirm whether the antibiotic is doxycycline hyclate or doxycycline monohydrate, then check the stated doxycycline-equivalent strength. Request the approved composition, including the lactic acid bacillus strain or strains and viable count at manufacture and at the end of shelf life.
A separate certificate for each ingredient does not prove the finished combination has the declared content.
2. Verify the dosage form. The specification should state whether it is an immediate-release capsule, delayed-release capsule, or another form, and identify the capsule shell, excipients, and packaging. Ask for compatibility data showing that doxycycline exposure, moisture, temperature, and excipients do not destroy the probiotic during manufacture or storage.
3. Read the proposed label and dispensing instructions, not only the formula sheet. Doxycycline absorption falls when it chelates with aluminium, calcium, magnesium, iron, or other polyvalent cations, so the artwork must state the required separation from interacting products.
It should also give the probiotic’s storage temperature, administration instructions, and any warning against opening or mixing the capsule.
Reject a formulation that reports only total bacterial count. The manufacturer must identify the strain with a validated method and distinguish probiotic enumeration from microbial-limit testing for objectionable organisms. An immediate-release capsule with a strong antibiotic assay is not adequate if the labelled lactic acid bacillus has lost viability.
Demand evidence that the probiotic survives manufacture and storage
A release certificate showing the initial probiotic count proves only that the capsule started compliant. Demand stability data for the finished capsule, stored in its proposed packaging and labelled conditions, with results at manufacture, scheduled intervals, and the end of shelf life.
| Test result | What it must show | What it proves |
|---|---|---|
| Strain authentication and enumeration | The named lactic-acid-bacillus strain is identified by a validated method, with viable count reported as CFU per dose | The declared organism, not merely “Lactobacillus,” is present |
| Real-time stability | CFU at expiry remains at or above the purchase specification under the labelled storage conditions | The probiotic survives the stated shelf life |
| Accelerated stability | Viable-count trends under elevated temperature and humidity, with supporting time points | Likely loss of viability and packaging weaknesses are detected sooner |
| Doxycycline stability | Assay, related substances or degradation products, and any required dissolution result remain within the approved specification at expiry | The antibiotic remains chemically and functionally compliant |
Ask for the guaranteed CFU through expiry, not only the count at batch release. Real-time data is the direct evidence; accelerated data supports the conclusion but cannot replace it.
The manufacturer must separate probiotic enumeration from finished-product microbial-limit testing. A total plate count does not confirm the declared strain. Request results for objectionable organisms and contamination controls, plus the method validation showing that doxycycline does not suppress recovery of the probiotic during testing.
Reject a claim based only on capsule appearance, initial CFU, or an acceptable doxycycline assay.
Review the quality documents behind every released batch
A released-batch file should trace the doxycycline API and probiotic culture through dispensing, encapsulation, packaging, testing, approval, and any complaint investigation. A catalogue, sample, and generic GMP certificate do not prove control of this specific capsule.
| Record | Inspect | What it demonstrates |
|---|---|---|
| Batch manufacturing record and packaging record | Material lot numbers, quantities, equipment, operators, yields, line clearance, reconciliation, and pack codes | Traceability and control of mix-ups or undocumented substitutions |
| Finished-product specification and certificate of analysis | Assay, related substances, content uniformity, dissolution testing, capsule appearance, and microbiological limits | Doxycycline quality and compliance with release criteria |
| Microbiology report | Validated identification and viable-count method for the declared strain, plus tests for objectionable organisms and contamination | Probiotic identity and safety; total plate count alone is insufficient |
| Analytical raw data | Chromatograms, calculations, instrument IDs, method versions, timestamps, audit trails, and independent review | Reliable results rather than edited or reconstructed records |
| Quality-system file | Supplier qualification, deviations, CAPA, change control, cleaning validation, stability summary, excursion policy, and recall procedure | Ongoing control across antibiotic and live-microbial operations |
Ask for the approved master formula and confirm that every result belongs to the stated batch number. Missing original data, unexplained overwriting, identical chromatograms across batches, or unsigned corrections indicate a data-integrity failure.
The manufacturer should explain how an out-of-specification result is investigated and link the decision to release or reject the batch. For export or third-party supply, retain these records with the product-specific license and retain-sample policy.
Use a supply and compliance checklist before appointing a partner
A catalogue, sample, and generic GMP certificate are not enough to appoint a supplier. Compare the partner’s control of this exact capsule, its delivery channel, and its support after release.
| Supply route | Evidence to compare | Disqualifying gap |
|---|---|---|
| PCD pharma franchise | Product-specific licence, approved artwork, territory terms, replacement policy | No proof the fixed-dose combination is authorised |
| Third-party manufacturing | Approved master formula, batch records, finished-product specification, certificate of analysis | Only a quotation and sample |
| Export supply | Marketing authorisation or registration basis, export documentation, language-compliant artwork, shipping conditions | No destination-country dossier or excursion policy |
Request real-time and accelerated stability data through expiry, including probiotic counts at the labelled storage condition. Confirm the high-barrier blister or bottle, validated closure, and desiccant requirement with container-closure data. Ensure the information leaflet and export artwork state separation from aluminium, calcium, magnesium, and iron.
Use this appointment checklist:
- Verify the exact doxycycline salt, strength, strain identity, viable count at manufacture and expiry, dosage form, pack size, and proposed indication.
- Request the approved master formula, batch manufacturing and packaging records, stability summary, and batch-specific certificate of analysis.
- Ask how it investigates deviations, handles storage excursions, manages complaints, and operates a documented recall system.
- Confirm bioequivalence strategy and comparative dissolution data when the target regulator requires them.
If Chemsroot Pharmaceutical is considered, assess its proposal against this same product-specific file rather than its broader doxycycline or probiotic catalogue. A partner that cannot explain replenishment lead times, retained samples, complaint response, and post-launch documentation is not ready for recurring PCD, third-party manufacturing, or export supply.
Frequently asked questions
Why must you verify authorization for the exact doxycycline and lactic acid bacillus combination?
Separate licences for doxycycline and probiotics do not prove approval for the fixed-dose capsule. Confirm authorization for the exact combination in your target market.
What formulation details should you check before comparing manufacturers?
Compare the stated strengths, capsule composition, excipients, manufacturing process, storage conditions, and documented interaction controls for doxycycline and lactic acid bacillus.
How can you assess whether the probiotic survives manufacture and storage?
Ask for stability data, potency results at release and through the stated shelf life, storage conditions, and evidence that the finished capsule protects viable probiotic cells.
Which quality documents should you request for each released batch?
Request the batch manufacturing record, certificate of analysis, test results, release approval, traceability details, and copies of applicable manufacturing licences.
Keywords
